SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Entest BioMedical Inc. (ENTB)

ENTB RSS Feed
Add ENTB Price Alert      Hide Sticky   Hide Intro
Moderator: ronrooster
Search This Board: 
Last Post: 8/18/2017 12:00:42 PM - Followers: 443 - Board type: Free - Posts Today: 0

                                    
http://www.barchart.com/headlines/story/8402740/entest-biomedical-inc-in-discussions-to-acquire-nanotechnology-delivery-system-for-cancer-therapy

Picture
 
Brian Devine, Chairman
Business Advisory Board

 
Brian is the former Chairman, CEO, and President of PETCO, where he oversaw the company’s expansion from $80 million to approximately $5 billion in sales. He became Chairman Emeritus at Petco Holdings, Inc. in 2016. Prior to that, he held leadership roles at Toys R Us, including Senior Vice President, Director of Stores for the U.S and Canada. Brian served as a Director at National Retail Federation Inc., Retail Industry Leaders Association, Students in Free Enterprise, Georgetown University Board of Regents, Georgetown University College Board of Advisors, San Diego International Sports Council, and the San Diego Padres.  He also served as Director, Chairman of Real Estate Committee, Member of Executive Committee and Member of Nominating Committee at Wild Oats Market prior to it being sold to Whole Foods. He currently is on the Board of Directors of the Ron Fowler School of Business at San Diego State University, the San Diego Sports Alliance, the San Diego Hall of Champions, and on private company boards.



 

http://www.zandertherapeutics.com


 

PRODUCT PIPELINE | ZANDER THERAPEUTICS, INC

?Zander Therapeutics is a biotechnology company focused on veterinary therapies that enlist the animals’ own immune system.  Zander’s main areas of interest include: autoimmune disorders such as arthritis, immunotherapies for cancer treatment in canines and bone marrow suppression therapy for animals treated with chemotherapy and radiation therapy.
?
Picture
 
??Learn more about bone marrow and aplastic anemia therapy as well as small molecule targeting cancer stem cell genes.
 

 

Products in Development for Veterinary Use

  • ZT 110 is an NR2F6 inhibitor feline leukemia
    ZT 240 is an NR2F6 inhibitor for canine cancer
    ?ZT 396 is an NR2F6 stimulator for exercise induced pulmonary hemorrhage (equine)
    ZT 430 is an NR2F6 stimulator for arthritis and autoimmunity (feline & canine)
 

 

Small Molecule Therapies Targeting Cancer Stem Cell Genes in Animals?

Small Molecule targeting of the cancer stem cell is the process of “coaxing” the cancer stem cell to turn into a normal cell. Regen BioPharma (licensor) has identified and filed patents on a novel gene controlling the process of cancer stem cell differentiation. Additionally, Zander Therapeutics has filed its own patent applications regarding therapies for animals.?
  • Objective is to identify small molecules that can induce differentiation of cancer stem cells 
    High through-put screening identified 7 “hit” compounds 
    Currently in pre-clinical development 
    Additional indications include solid tumors and acute leukemia
 

 

Small Molecule Therapies Targeting Autoimmune Diseases Genes in Animals

The Company believes that autoimmune diseases such as arthritis can be controlled and their impact reversed by activating a gene in animals that is believed to modulate this process.  This set of therapies is based upon intellectual property licensed by Zander Therapeutics from Regen BioPharma.  Zander Therapeutics is pursuing its own intellectual property that will build on currently licensed technology.
  • Objective is to identify small molecules that activate NR2F6 check point that appears to control autoimmune diseases

    Currently in pre-clinical development 
 

 

Bone Marrow and Aplastic Anemia Therapy

A personalized cellular therapeutic product designed to stimulate blood production in veterinary patients whose bone marrow is not properly functioning.
  • Fat stem cell-based product to treat bone marrow that has been damaged
    Bone marrow damage occurs from radiation, chemotherapy or chronic conditions
    Uses animal’s own fat as a source of endothelial cells to heal damaged bone marrow 
    Toxicity studies have been successfully completed by Regen BioPharma Inc., the licensor of this technology to Zander Therapeutics
    Aims to provide “natural” replacement to synthetic cytokines
?
For cats and dogs, Zander will target:
  • Arthritis
    Cancer
    Autoimmune Disorders
    Feline Leukemia

For horses, Zander will target:
  • Exercise Induced Pulmonary Hemorrhage (EIPH)

United States Food and Drug Administration (FDA) Investigational New Drug Application (IND #15376, status cleared for use in humans by Regen BioPharma Inc. -- licensor to Zander Therapeutics Inc.)

 

 

 

 

 

Address:
Zander Therapeutics, Inc.
4700 Spring Street, Suite 304
La Mesa, CA 91942
U.S.A.

?venturebridge@gmail.com
Telephone: (619) 702-1404
Fax: (619) 330-2328


 

MANAGEMENT & ADVISORY TEAM | ZANDER THERAPEUTICS, INC.

Picture
 
David R. Koos, PhD, DBA
Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 32 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.
 

 
Picture
 
?Harry Lander, PhD, MBA
President and Chief Scientific Officer


Harry Lander has over 20 years of professional scientific, business and financial management experience related to biomedical research.  He has a deep knowledge of operations and research administration.  Dr. Lander has a team-oriented management style founded on outstanding communication and interpersonal skills.  Highly effective at strategic planning, problem solving and operational excellence.  Dr. Lander has extensive relationships with large and small biotechnology / pharmacology companies and entities that Regen BioPharma expects to leverage for company growth.

Formerly he has served as Research Chief / Administration for Sidra Medical and Research Center (Doha, Qatar), Assistant Provost for Weill Cornell Medical College (Cornell University), along with serving as Assistant Dean for Research Administration at Weill Cornell Medical College (Cornell University).
 

 
Picture
 
?Todd S. Caven
Chief Financial Officer 


Todd S. Caven is an accomplished executive with 30 years of experience in corporate finance, taxation, mergers & acquisitions, corporate valuations and financing activities for various types of transactions. In March of 2009, Mr. Caven co-founded Saguaro Capital Partners, an Arizona based firm that raises growth capital for medical device, pharmacology and technology based companies throughout the western United States.

In 2003, Mr. Caven founded Rock Ridge Enterprises, a Minnesota-based boutique Private Equity firm that focuses on the acquisition of manufacturing, distribution, construction and business services firms in the upper Midwest. Prior to founding Rock Ridge Enterprises, he served as the CFO of Atterro Human Capital Group (formerly Pro Staff), a $500 million privately held firm in the Staffing and Recruiting industry. Prior to Atterro, Todd held senior-level finance and marketing positions at Nordic Track and the Carlson Companies, both in Minneapolis, Minnesota. He started his career in corporate finance at Amoco Corporation in Chicago, Illinois (now British Petroleum).

Todd earned a Bachelors degree in Accounting from the Tippie College of Business at the University of Iowa, and he received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University.
 

 
Picture
 
Thomas Donnelly, DVM
Senior Veterinary Advisor
?

Tom is a board-certified specialist in the field of laboratory animal medicine. He is also Adjunct Associate Professor at Tufts University Cummings School of Veterinary Medicine and Professor (teaching & research) at Ecole Nationale Veterinaire d’Alfort. He provides regulatory guidance, research advice, medical attention and welfare supervision to researchers using animals in scientific investigation and testing. Tom is a board-certified specialist in the field of exotic mammals, and sees primary care and referred patients. His work links the understanding of animal diseases and their complexities with the development of novel therapies for humans and animals.
 

 
Picture
 
Linda L. Black, DVM, PhD 
Senior Veterinary Advisor

Linda is a leading researcher, published author and currently COO and Vice President of Clinical Science for Medicus Biosciences, a biotech company focused on drug delivery for ophthalmology, advanced wound healing, osteoarthritis, and regenerative medicine applications for pets and people. She has extensive experience in veterinary stem cell research and commercialization. She holds a PhD in Molecular and Cell Biology from The Wistar Institute at University of Pennsylvania School of Medicine, a DVM from University of Wisconsin School of Veterinary Medicine and attended undergraduate training at the University of California at Davis. She completed her post doctoral fellowship at GlaxoSmithKline.
 

 
Picture
 
?Thomas Ichim, PhD
Senior Research Consultant


Dr. Ichim has extensive experience with stem cell therapy and cellular product development through FDA regulatory pathways. He spent over seven years as President and Chief Scientific Officer of Medistem, developing and commercializing a novel stem cell, the Endometrial Regenerative Cell, through drug discovery, optimization, preclinical testing, IND filing, and up through Phase II clinical trials with the FDA. Subsequent to the acquisition of Medistem by Intrexon, in a deal worth $26 million, Dr. Ichim was brought on to the parent company in its cell engineering unit as Vice President of Cellular Therapy. 
 

 
Picture
 
?Debbie Dorsee
Director of Business Development

The Dorsee Company, founded by Debbie Dorsee, is a leader in public relations for businesses and individuals. With an integrated focus on community relations, marketing, fundraising/capital raising, and business development, The Dorsee Company offers a unique promotional approach that opens doors, forges partnerships, and drives results.
?
Debbie Dorsee, a San Diego native, founded The Dorsee Company in 2003. Drawing from her life’s fabric of political campaigns, social events and promotional fundraising, she uses her behind-the-scenes knowledge and community contacts to promote public awareness and drive business results. Debbie was the recipient of the San Diego North Chamber of Commerce’s Volunteer of the Year honor and was named one of San Diego Metropolitan Magazine’s Metro Movers to Watch

Jonathan Baell, PhD
Scientific Advisory Board


Dr. Baell is a professor or Medicinal Chemist at Monash University (Australia) whose research is focused on the discovery of new medicines for treating diseases with an unmet medical need. A proven record of undertaking original research with a total of 120 publications and patents. He is published in top-ranked journals in the field (e.g. 12 in Journal of Medicinal Chemistry, Nature Chemical Biology,Nature).  He has 40 granted patents listed in www.lens.org.

He has won a national award for my discovery of a new class of potential multiple sclerosis therapeutics. Additionally he has achieved successful outcomes in a diverse array of drug discovery arenas, from rational design of peptidomimetics to heterocyclic drug discovery.

For the period 2012-16, Dr. Baell is Chief InvestIgator on competitive grants that currently are totalling $4.73M. In addition, he has been awarded a prestigious NHMRC Senior Research Fellowship for the period 2012-2016. In 2011 and elected as the Australian representative to the Board of Directors for the Inaugural International Chemical Biology Society and appointed Chair of Membership.

 
 

 Recent News!  Check out Zander therapeutics website.

 

 

 

 

ENTB
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ENTB News: Quarterly Report (10-q) 06/22/2017 02:11:24 PM
ENTB News: Current Report Filing (8-k) 05/31/2017 06:08:12 AM
ENTB News: Current Report Filing (8-k) 05/25/2017 06:06:14 AM
ENTB News: Quarterly Report (10-q) 04/03/2017 02:19:18 PM
PostSubject
#38167  Sticky Note Here we go.....Zander Therapeutics, Inc. Reports Research Demonstrating ronrooster 07/26/17 11:15:48 AM
#38189   Obviously Market manager code.No clue as to its ronrooster 08/18/17 12:00:42 PM
#38188   67 shares ??? salesleader 08/18/17 11:35:23 AM
#38187   Let's see if we get some real news ronrooster 08/15/17 12:25:24 PM
#38186   With some SOLID News, this wall will be ronrooster 08/12/17 10:17:46 AM
#38185   I smell news...there is a 500k wall at gotinearly 08/10/17 10:42:14 AM
#38184   Thank JW for your insight.The potential is ronrooster 08/09/17 04:14:36 PM
#38183   The company is very confident in what they JokersWild12 08/09/17 03:59:46 PM
#38182   NAIL on the head.Exactly.ENTB/ZANDER may be ready to ronrooster 08/09/17 02:02:04 PM
#38181   They are only 6-12 months behind IFM Therapeutics JokersWild12 08/09/17 01:58:10 PM
#38180   Thanks for posting.I guess ENTB/ZANDER will ronrooster 08/09/17 11:48:06 AM
#38179   RGBP NEWS JokersWild12 08/09/17 10:28:06 AM
#38178   IMO we are due for some substantial news ronrooster 08/08/17 12:14:00 PM
#38177   Anyone know what code 15 means ?( 15 ronrooster 08/03/17 12:08:41 PM
#38176   Google alerts coming thru now.It will only take ronrooster 07/27/17 01:58:58 PM
#38175   Mirror trades taking us down now.Looks like someone ronrooster 07/27/17 10:47:13 AM
#38174   And salesleader makes 3 , LOL salesleader 07/26/17 05:08:10 PM
#38173   Excellent summary. A little more patience I guess.gltu2 ronrooster 07/26/17 12:36:22 PM
#38172   We know that they have had discussions though JokersWild12 07/26/17 12:22:56 PM
#38171   $11 trade to knock down 17%. Maybe the ronrooster 07/26/17 12:07:31 PM
#38170   That will change soon.Wonder how many current shareholders ronrooster 07/26/17 12:02:00 PM
#38169   Well at least there are two people looking JokersWild12 07/26/17 11:49:39 AM
#38168   NEWS.. Zander Therapeutics, Inc. Reports Research Demonstrating Ex-Vivo Immun JokersWild12 07/26/17 11:16:23 AM
#38167   Here we go.....Zander Therapeutics, Inc. Reports Research Demonstrating ronrooster 07/26/17 11:15:48 AM
#38166   Wish I have an doctorate, however we are ronrooster 07/25/17 01:13:54 PM
#38165   RGBP NEWS: JokersWild12 07/25/17 09:05:15 AM
#38164   OVERDUE! hopefully we all have enough shares to ronrooster 07/24/17 08:20:20 PM
#38163   News is due. Its been a month since JokersWild12 07/24/17 03:43:35 PM
#38162   $ENTB Kbro13 07/13/17 02:52:57 PM
#38161   ENTB this could be huge for the cousins. sizzleweed 07/12/17 09:15:00 PM
#38160   $ENTB .04's FightingBack 07/12/17 02:21:42 PM
#38159   It's all good because the news applies to JokersWild12 07/12/17 11:18:00 AM
#38158   Excellent.It would have been nice if ENTB/ZANDER had ronrooster 07/12/17 10:57:30 AM
#38157   NEWS-Regen BioPharma, Inc. Researchers Discover New Dynamic Compound JokersWild12 07/12/17 09:57:25 AM
#38156   You've called it before. The company has been JokersWild12 07/08/17 01:45:58 PM
#38155   Spider sense tingling-News next Wednesday-summer of 2017 hit! Imo. ronrooster 07/08/17 01:06:57 PM
#38154   Dresden01. True, someone with the credentials that he JokersWild12 06/28/17 11:22:01 AM
#38153   ANOTHER SIGNIFICANT ADDITION TO ZANDER BOARDJonathan Baell, PhD ronrooster 06/27/17 04:19:48 PM
#38152   Picture ronrooster 06/27/17 04:17:57 PM
#38151   News/Google alerts coming thru now,impact of news should ronrooster 06/27/17 03:08:27 PM
#38150   things are coming together piece by piece. jeffshir 06/27/17 01:58:16 PM
#38149   I don't know why this is not trading Dresden01 06/27/17 01:44:21 PM
#38148   Btw, ENTB is in a great spot. I Dresden01 06/27/17 01:04:41 PM
#38147   I think that this announcement is pretty SIGNIFICANT. Dresden01 06/27/17 01:01:09 PM
#38146   No problem.Once we get thru the 1/2 million ronrooster 06/27/17 12:38:27 PM
#38145   It's just a matter of time. The company JokersWild12 06/27/17 12:16:22 PM
#38144   Thanks JW for posting this excellent news.ENTB/ZANDER is ronrooster 06/27/17 10:50:43 AM
#38143   Zander Therapeutics Inc. Announces Brian Devine, Former Chairman JokersWild12 06/27/17 09:03:40 AM
#38142   10 Q is out.Share structure still good. ronrooster 06/22/17 02:23:28 PM
#38141   Wonder if we get another Wednesday PR this ronrooster 06/19/17 11:22:28 AM
#38140   Unlimited potential .Perhaps ENTB should change its ticker symbol.gltu. ronrooster 06/18/17 01:10:17 PM
PostSubject